Mallinckrodt was previously described by the US Drug Enforcement Administration as the “kingpin” of pharmaceutical companies driving the opioid epidemic in the US, which saw an explosion in prescription, misuse, addiction and overdoses linked to heavy painkillers.
The partnership has continued in recent years despite the manufacturer being increasingly embroiled in controversy over its role in the prescription opioid crisis. Records show Coolmine continued its partnership with the drug maker after this point, with Mallinckrodt disclosing a further €4,700 donation to the centre in 2020.
“Coolmine has a clear and defined set of principles which govern our organisation, with honesty, consistency, and responsibility at the heart of everything we do for clients,” Ms McKeown said. “All of our corporate sponsors have demonstrated the same values in their generosity and support of the charity.”